Why the study?
Sacubitril/valsartan is a standard therapy for heart failure, and whether adding Shexiang Baoxin Pill confers additional clinical benefits remained to be systematically investigated.
Comparison
Shexiang Baoxin Pill plus sacubitril/valsartan vs sacubitril/valsartan alone
Design
Systematic review and meta-analysis of randomized controlled trials
Answers are grounded in this paper and cite their sources.
Supports adding shexiang baoxin pill to sacubitril/valsartan; extends meta-analytic evidence for adjunctive HF therapy.
Background Shexiang Baoxin Pill (SBP), a well-known Chinese patent medicine derived from Suhexiang Pill, has long been used for heart failure management, owing to its potential cardioprotective effects through anti-inflammatory, anti-oxidative, and anti-fibrotic mechanisms. While sacubitril/valsartan is considered as a standard therapy for heart failure, whether adding SBP confers additional clinical benefits remains to be systematically investigated. Objective To assess the efficacy and safety of SBP combined with sacubitril/valsartan in patients with heart failure. Methods Randomized controlled trials (RCT) comparing SBP plus sacubitril/valsartan versus sacubitril/valsartan alone were identified through a comprehensive search of PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and the Chinese Biomedical Literature Database (CBM) databases from inception to June 19, 2026, supplemented by manual searches of the Chinese Clinical Trial Registry (ChiCTR) and ClinicalTrials.gov . Two reviewers independently screened records, assessed eligibility, extracted data, and evaluated risk of bias using the Cochrane RoB 2 tool. Meta-analyses were conducted using R software, and the certainty of evidence was graded following the GRADE approach. Results Fifteen RCTs involving 1,483 patients were included. Compared with sacubitril/valsartan alone, the addition of SBP significantly improved cardiac function, as evidenced by increases in left ventricular ejection fraction [MD = 5.06, 95% CI (4.23, 5.90)], cardiac output [MD = 0.77, 95% CI (0.50, 1.05)], and stroke volume [MD = 6.72, 95% CI (2.72, 10.71)], all with P values < 0.001. Functional capacity was also improved, as reflected by a significant increase in 6-minute walk distance [MD = 52.12, 95% CI (34.90, 69.33), P < 0.001]. Meanwhile, left ventricular remodeling parameters, including end-diastolic diameter [MD = −5.57, 95% CI (−6.53, −4.61), P < 0.001], end-systolic diameter [MD = −5.42, 95% CI (−6.63, −4.20), P < 0.001], and end-diastolic volume [MD = −14.73, 95% CI (−25.67, −3.80), P = 0.008] were also apparently reduced following combination treatment. Concurrent with these structural enhancements, levels of N-terminal pro-B-type natriuretic peptide [MD = −261.55, 95% CI (−506.88, −16.23), P = 0.037] and B-type natriuretic peptide [MD = −165.37, 95% CI (−243.32, −87.42), P < 0.001] decreased notably. Notably, no significant difference in adverse event incidence was observed between groups [RR = 1.02, 95% CI (0.69, 1.50), P = 0.921]. The certainty of evidence was rated as low to very low for most outcomes, primarily due to methodological limitations and substantial heterogeneity. Conclusion The available evidence indicates that combining SBP with sacubitril/valsartan may provide additional therapeutic benefits in heart failure patients without a clear increase in adverse events. However, these findings must be interpreted with caution given the low certainty of evidence. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261433431 , identifier CRD420261433431.
No takes yet. Share an insight, caveat, or question.
温文倩 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: